Skip to main content

Table 1 Patient demographic characteristics*

From: Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010

 

12 months

24 months

36 months

 

Overall

GA

Overall

GA

Overall

GA

N

35,312

12,144

21,927

7,386

14,315

4,693

Age

      

≤18

0.6%

0.7%

0.7%

0.7%

0.8%

0.8%

19-35

22.4%

21.7%

21.1%

20.5%

19.2%

18.8%

36-50

50.2%

50.3%

51.5%

51.7%

52.3%

52.4%

51-62

24.2%

24.5%

24.5%

24.6%

25.6%

25.7%

≥63

2.6%

2.8%

2.3%

2.5%

2.2%

2.2%

Gender

      

Female

76.5%

78.2%

76.7%

78.6%

76.6%

78.6%

  1. *Cohorts are subsets of one another.